Expressional/JJ
Subpopulation/NN
of/IN
Cancers/NNS
Determined/JJ
by/IN
G64/NN
,/,
a/DT
Co-regulated/JJ
Module/NN
./.
====================
Studies/NNS
of/IN
cancer/NN
heterogeneity/NN
have/VBP
received/VBN
considerable/JJ
attention/NN
recently/RB
,/,
because/IN
the/DT
presence/NN
or/CC
absence/NN
of/IN
resistant/JJ
sub-clones/NNS
may/MD
determine/VB
whether/IN
or/CC
not/RB
certain/JJ
therapeutic/JJ
treatments/NNS
are/VBP
effective/JJ
./.
====================
Previously/RB
,/,
we/PRP
have/VBP
reported/VBN
G64/NN
,/,
a/DT
co-regulated/JJ
gene/NN
module/NN
composed/VBN
of/IN
64/CD
different/JJ
genes/NNS
,/,
can/MD
differentiate/VB
tumor/NN
intra-/NN
or/CC
inter-subpopulations/NNS
in/IN
lung/NN
adenocarcinomas/NNS
(/(
LADCs/NNS
)/)
./.
====================
Here/RB
,/,
we/PRP
investigated/VBD
whether/IN
the/DT
G64/NN
module/NN
genes/NNS
were/VBD
also/RB
expressed/VBD
distinctively/RB
in/IN
different/JJ
subpopulations/NNS
of/IN
other/JJ
cancers/NNS
./.
====================
RNA/NN
sequencing-based/VBN
transcriptome/VBP
data/NNS
derived/VBN
from/IN
22/CD
cancers/NNS
,/,
except/IN
LADC/NN
,/,
were/VBD
downloaded/VBN
from/IN
The/DT
Cancer/NN
Genome/NN
Atlas/NNS
(/(
TCGA/NN
)/)
./.
====================
Interestingly/RB
,/,
the/DT
22/CD
cancers/NNS
also/RB
expressed/VBD
the/DT
G64/NN
genes/NNS
in/IN
a/DT
correlated/JJ
manner/NN
,/,
as/IN
observed/VBN
previously/RB
in/IN
an/DT
LADC/NN
study/NN
./.
====================
Considering/VBG
that/DT
gene/NN
expression/NN
levels/NNS
were/VBD
continuous/JJ
among/IN
different/JJ
tumor/NN
samples/NNS
,/,
tumor/NN
subpopulations/NNS
were/VBD
investigated/VBN
using/VBG
extreme/JJ
expressional/JJ
ranges/VBZ
of/IN
G64—i.e./FW
,/,
tumor/NN
subpopulation/NN
with/IN
the/DT
lowest/JJ
15/CD
%/NN
of/IN
G64/NN
expression/NN
,/,
tumor/NN
subpopulation/NN
with/IN
the/DT
highest/JJS
15/CD
%/NN
of/IN
G64/NN
expression/NN
,/,
and/CC
tumor/NN
subpopulation/NN
with/IN
intermediate/JJ
expression/NN
./.
====================
In/IN
each/DT
of/IN
the/DT
22/CD
cancers/NNS
,/,
we/PRP
examined/VBD
whether/IN
patient/NN
survival/NN
was/VBD
different/JJ
among/IN
the/DT
three/CD
different/JJ
subgroups/NNS
and/CC
found/VBD
that/IN
G64/NN
could/MD
differentiate/VB
tumor/NN
subpopulations/NNS
in/IN
six/CD
other/JJ
cancers/NNS
,/,
including/VBG
sarcoma/NN
,/,
kidney/NN
,/,
brain/NN
,/,
liver/NN
,/,
and/CC
esophageal/JJ
cancers/NNS
./.
====================
Different/JJ
tumors/NNS
or/CC
cancers/NNS
in/IN
different/JJ
patients/NNS
have/VBP
distinct/JJ
genetic/JJ
and/CC
cellular/JJ
profiles/NNS
,/,
including/VBG
kinds/NNS
of/IN
genetic/JJ
mutations/NNS
,/,
patterns/NNS
of/IN
gene/NN
expression/NN
,/,
and/CC
metastatic/JJ
potential/JJ
,/,
which/WDT
is/VBZ
often/RB
called/VBN
cancer/NN
heterogeneity/NN
./.
====================
The/DT
heterogeneity/NN
occurs/VBZ
both/CC
within/IN
and/CC
between/IN
tumors/NNS
and/CC
leads/VBZ
to/TO
intra-tumor/NN
heterogeneity/NN
and/CC
inter-tumor/NN
heterogeneity/NN
,/,
respectively/RB
[/(
123/CD
]/)
./.
====================
Understanding/VBG
cancer/NN
heterogeneity/NN
has/VBZ
recently/RB
been/VBN
one/CD
of/IN
the/DT
important/JJ
research/NN
subjects/NNS
,/,
because/IN
it/PRP
is/VBZ
the/DT
base/NN
of/IN
difficulty/NN
in/IN
developing/VBG
effective/JJ
cancer/NN
treatments/NNS
./.
====================
Tumor/NN
heterogeneity/NN
is/VBZ
basically/RB
due/JJ
to/TO
the/DT
different/JJ
origins/NNS
of/IN
tumor/NN
cells/NNS
or/CC
tissues/NNS
./.
====================
Various/JJ
biological/JJ
factors/NNS
,/,
such/JJ
as/IN
smoking/NN
,/,
gender/NN
,/,
age/NN
,/,
or/CC
hormonal/JJ
status/NN
,/,
can/MD
influence/VB
cancer/NN
initiation/NN
or/CC
progression/NN
,/,
as/IN
well/RB
./.
====================
Fundamentally/RB
,/,
there/EX
are/VBP
genetic/JJ
variations/NNS
among/IN
the/DT
hosts/NNS
,/,
even/RB
for/IN
the/DT
same/JJ
cancer/NN
[/(
456/CD
]/)
./.
====================
Astonishingly/RB
rapid/JJ
development/NN
of/IN
massively/RB
parallel/NN
sequencing/NN
,/,
alternatively/RB
called/VBN
nextgeneration/NN
sequencing/NN
technologies/NNS
,/,
has/VBZ
recently/RB
elucidated/VBN
the/DT
extent/NN
of/IN
tumor/NN
heterogeneity/NN
,/,
and/CC
several/JJ
hundred/JJ
somatic/JJ
mutations/NNS
and/CC
structural/JJ
variants/NNS
that/IN
drive/VBP
cancers/NNS
have/VBP
been/VBN
identified/VBN
[/(
789/CD
]/)
./.
====================
Previously/RB
,/,
we/PRP
reported/VBD
the/DT
characterization/NN
of/IN
the/DT
heterogeneity/NN
of/IN
human/JJ
lung/NN
adenocarcinomas/NNS
(/(
LADCs/NNS
)/)
from/IN
patient-derived/JJ
xenografts/NNS
via/IN
single-cell/JJ
transcriptome/VBP
sequencing/NN
[/(
10/CD
]/)
./.
====================
These/DT
cells/NNS
were/VBD
categorized/VBN
into/IN
two/CD
separate/JJ
subpopulations/NNS
based/VBN
on/IN
their/PRP$
expression/NN
of/IN
a/DT
module/NN
gene/NN
named/VBD
G64/NN
./.
====================
We/PRP
found/VBD
that/IN
G64/NN
upregulation//IN
down-regulation/NN
was/VBD
also/RB
present/JJ
in/IN
patient/NN
tissue/NN
samples/NNS
obtained/VBN
from/IN
the/DT
Cancer/NN
Genome/NN
Atlas/IN
(/(
TCGA/NN
)/)
,/,
with/IN
G64/NN
up-regulation/NN
corresponding/VBG
to/TO
poor/JJ
survival/NN
and/CC
associated/VBN
with/IN
multiple/JJ
clinical/JJ
variables/NNS
,/,
such/JJ
as/IN
smoking/JJ
status/NN
(/(
which/WDT
exhibited/VBD
the/DT
highest/JJS
correlation/NN
)/)
and/CC
tumor/NN
stage/NN
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
investigated/VBD
if/IN
G64/NN
can/MD
differentiate/VB
tumor/NN
subpopulations/NNS
in/IN
other/JJ
cancers/NNS
,/,
as/IN
well/RB
./.
====================
Websites/NNS
for/IN
downloading/VBG
RNA/NN
sequencing/NN
(/(
RNA-seq/NN
)/)
data/NNS
for/IN
22/CD
cancer/NN
datasets/NNS
====================
The/DT
TCGA/NN
website/JJ
(/(
https/NNS
:/:
//tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp/JJ
)/)
was/VBD
used/VBN
for/IN
downloading/VBG
RNA-seq-based/JJ
transcriptome/VBP
data/NNS
and/CC
patient/NN
survival/NN
information/NN
for/IN
22/CD
cancers/NNS
./.
====================
The/DT
RNA-seq/NN
data/NNS
downloaded/VBD
for/IN
each/DT
cancer/NN
are/VBP
listed/VBN
in/IN
Table/JJ
1/CD
and/CC
Supplementary/JJ
Table/JJ
1/CD
./.
====================
As/IN
described/VBN
in/IN
the/DT
previous/JJ
report/NN
[/(
10/CD
]/)
,/,
expression/NN
values/NNS
of/IN
0/CD
</JJR
FPKM/NN
(/(
fragments/NNS
per/IN
kilobase/NN
of/IN
exon/NN
per/IN
million/NN
fragments/NNS
mapped/VBD
)/)
</JJR
0.1/CD
were/VBD
all/DT
converted/VBD
to/TO
0.1/CD
to/TO
avoid/VB
the/DT
infinity/NN
problem/NN
./.
====================
Each/DT
FPKM/NN
value/NN
of/IN
each/DT
gene/NN
was/VBD
divided/VBN
by/IN
the/DT
average/JJ
FPKM/NN
estimated/VBN
for/IN
the/DT
total/JJ
patient/NN
samples/NNS
where/WRB
the/DT
gene/NN
is/VBZ
expressed/VBN
and/CC
was/VBD
log2-transformed/VBN
,/,
for/IN
which/WDT
heat/NN
map/VBP
analysis/NN
combined/VBD
with/IN
hierarchical/JJ
clustering/NN
was/VBD
performed/VBN
with/IN
the/DT
'hclust/JJ
'/``
function/NN
of/IN
R/NN
package/NN
(/(
https/NNS
:/:
//stat.ethz.ch/R-manual/R-patched/library/stats/html/hclust.html/JJ
)/)
./.
====================
Statistical/JJ
tests/NNS
====================
We/PRP
used/VBD
R/NN
(/(
v/LS
3.1.3/CD
)/)
for/IN
all/DT
statistical/JJ
tests/NNS
(/(
https/NNS
:/:
//cran.r-project.org//JJ
)/)
./.
====================
Using/VBG
the/DT
factoMineR/NN
(/(
http/NN
:/:
//factominer.free.fr/JJ
)/)
and/CC
rgl/JJ
(/(
https/NNS
:/:
//r-forge.r-project.org/projects/rgl//JJ
)/)
packages/NNS
,/,
principal/JJ
component/NN
analysis/NN
(/(
PCA/NN
)/)
and/CC
visualization/NN
were/VBD
performed/VBN
[/(
11/CD
]/)
./.
====================
The/DT
survival/NN
packages/NNS
were/VBD
used/VBN
(/(
http/NN
:/:
//r-forge.r-project.org/JJ
)/)
to/TO
compare/VB
patient/NN
survival/NN
rates/NNS
and/CC
draw/VB
Kaplan-Meier/NN
plots/NNS
./.
====================
The/DT
coxph/NN
function/NN
in/IN
the/DT
survival/NN
packages/NNS
was/VBD
used/VBN
for/IN
performing/VBG
the/DT
Cox/NN
regression/NN
analysis/NN
[/(
1213/CD
]/)
./.
====================
Selection/NN
of/IN
two/CD
extreme/JJ
patient/NN
groups/NNS
and/CC
one/CD
intermediate/JJ
group/NN
determined/VBD
by/IN
G64/NN
expression/NN
====================
The/DT
G64/NN
genes/NNS
were/VBD
originally/RB
identified/VBN
by/IN
their/PRP$
coregulated/JJ
expression/NN
pattern/NN
in/IN
single/JJ
cells/NNS
derived/VBN
from/IN
a/DT
single/JJ
LADC/NN
tumor/NN
region/NN
[/(
10/CD
]/)
./.
====================
Interestingly/RB
,/,
we/PRP
have/VBP
reported/VBN
that/IN
488/CD
LADC/NN
patients/NNS
samples/NNS
downloaded/VBN
from/IN
the/DT
TCGA/NN
were/VBD
also/RB
separated/VBN
into/IN
two/CD
distinct/JJ
groups/NNS
by/IN
the/DT
G64/NN
genes/NNS
./.
====================
In/IN
the/DT
present/JJ
work/NN
,/,
we/PRP
examined/VBD
whether/IN
G64/NN
could/MD
be/VB
a/DT
classifier/NN
for/IN
other/JJ
cancers/NNS
,/,
as/IN
well/RB
./.
====================
For/IN
this/DT
analysis/NN
,/,
22/CD
RNA-seq-based/JJ
transcriptome/VBP
data/NNS
with/IN
a/DT
sample/JJ
size/NN
≥150/CD
were/VBD
retrieved/VBN
from/IN
the/DT
TCGA/NN
./.
====================
The/DT
threshold/JJ
of/IN
150/CD
was/VBD
selected/VBN
,/,
because/IN
it/PRP
was/VBD
considered/VBN
to/TO
be/VB
the/DT
minimum/JJ
number/NN
of/IN
samples/NNS
for/IN
statistical/JJ
tests/NNS
between/IN
different/JJ
groups/NNS
(/(
Table/JJ
1/CD
,/,
Supplementary/JJ
Table/JJ
1/CD
)/)
./.
====================
As/IN
done/RB
in/IN
the/DT
previous/JJ
LADC/NN
study/NN
[/(
10/CD
]/)
,/,
heat/NN
map/VBP
analysis/NN
was/VBD
performed/VBN
for/IN
each/DT
cancer/NN
type/NN
to/TO
see/VB
how/WRB
patient/NN
samples/NNS
were/VBD
separated/VBN
by/IN
G64/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
./.
====================
As/IN
shown/VBN
in/IN
Supplementary/JJ
Fig/NN
./.
====================
1/CD
,/,
the/DT
co-regulated/JJ
patterns/NNS
of/IN
G64/NN
expression/NN
were/VBD
confirmed/VBN
in/IN
all/DT
types/NNS
of/IN
cancers/NNS
we/PRP
tested/VBD
./.
====================
However/RB
,/,
distinct/JJ
two-group/NN
separations/NNS
were/VBD
not/RB
as/IN
evident/JJ
as/IN
the/DT
case/NN
for/IN
LADC/NN
./.
====================
Therefore/RB
,/,
we/PRP
classifies/VBZ
patient/NN
samples/NNS
further/RBR
into/IN
three/CD
different/JJ
categories/NNS
by/IN
using/VBG
a/DT
15/CD
%/NN
extreme/JJ
threshold/NN
of/IN
G64/NN
expression/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
2/CD
)/)
:/:
the/DT
highest/JJS
15/CD
%/NN
group/NN
,/,
the/DT
lowest/JJS
15/CD
%/NN
group/NN
,/,
and/CC
an/DT
intermediate/JJ
group/NN
./.
====================
For/IN
this/DT
purpose/NN
,/,
the/DT
patients/NNS
were/VBD
sorted/VBN
out/IN
by/IN
the/DT
intensity/NN
of/IN
the/DT
average/NN
FPKM/NN
values/NNS
of/IN
the/DT
G64/NN
genes/NNS
expressed/VBN
in/IN
each/DT
patient/NN
./.
====================
As/IN
a/DT
result/NN
,/,
for/IN
instance/NN
,/,
among/IN
a/DT
total/JJ
of/IN
531/CD
kidney/NN
renal/JJ
clear/JJ
cell/NN
carcinoma/NN
(/(
KIRC/NN
)/)
samples/NNS
,/,
160/CD
samples/NNS
were/VBD
assigned/VBN
into/IN
the/DT
two/CD
extreme/JJ
groups—the/DT
highest/JJS
15/CD
%/NN
and/CC
the/DT
lowest/JJS
15/CD
%/NN
—whereas/IN
the/DT
remaining/VBG
371/CD
samples/NNS
were/VBD
classified/VBN
into/IN
the/DT
intermediate/JJ
group/NN
./.
====================
G64/NN
up-regulating/VBG
cancers/NNS
tend/NN
to/TO
have/VB
a/DT
poor/JJ
prognosis/NN
in/IN
six/CD
different/JJ
cancers/NNS
====================
We/PRP
next/RB
investigated/VBD
whether/IN
patient/NN
survival/NN
was/VBD
significantly/RB
different/JJ
in/IN
these/DT
three/CD
groups/NNS
classified/VBD
by/IN
the/DT
average/NN
intensity/NN
of/IN
G64/NN
expression/NN
./.
====================
Patient/JJ
survival/NN
rates/NNS
were/VBD
compared/VBN
among/IN
the/DT
three/CD
patient/NN
groups/NNS
for/IN
each/DT
of/IN
the/DT
22/CD
cancers/NNS
./.
====================
As/IN
done/RB
in/IN
the/DT
LADC/NN
study/NN
,/,
we/PRP
performed/VBD
Kaplan-Meier/NN
analysis/NN
using/VBG
the/DT
patients/NNS
'/``
survival/NN
data/NNS
obtained/VBN
from/IN
the/DT
TCGA/NN
in/IN
each/DT
type/NN
of/IN
cancer/NN
./.
====================
Survival/NN
rates/NNS
were/VBD
compared/VBN
between/IN
the/DT
lowest/JJ
15/CD
%/NN
versus/CC
highest/JJS
15/CD
%/NN
groups/NNS
(/(
i.e./FW
,/,
P1/NN
comparison/NN
in/IN
Table/JJ
1/CD
)/)
,/,
the/DT
lowest/JJ
15/CD
%/NN
versus/CC
intermediate/JJ
groups/NNS
(/(
i.e./FW
,/,
P2/NN
comparison/NN
in/IN
Table/JJ
1/CD
)/)
,/,
and/CC
the/DT
intermediate/JJ
versus/CC
highest/JJS
15/CD
%/NN
groups/NNS
(/(
i.e./FW
,/,
P3/NN
comparison/NN
in/IN
Table/JJ
1/CD
)/)
./.
====================
PCA/NN
confirmed/VBD
the/DT
groups/NNS
'/``
separations/NNS
by/IN
G64/NN
expression/NN
(/(
Fig/NN
./.
====================
1/CD
,/,
Supplementary/JJ
Fig/NN
./.
====================
3/CD
,/,
4/CD
,/,
5/CD
,/,
6/CD
,/,
7/CD
)/)
./.
====================
As/IN
summarized/VBN
in/IN
Table/JJ
1/CD
,/,
only/RB
six/CD
cancers/NNS
were/VBD
shown/VBN
to/TO
have/VB
statistically/RB
significant/JJ
differences/NNS
between/IN
groups/NNS
,/,
including/VBG
KIRC/NN
,/,
brain/NN
lower/JJR
grade/NN
glioma/NN
,/,
liver/NN
hepatocellular/JJ
carcinoma/NN
,/,
kidney/NN
renal/JJ
papilloma/NN
cell/NN
carcinoma/NN
,/,
esophageal/JJ
carcinoma/NN
,/,
and/CC
sarcoma/NN
./.
====================
In/IN
all/DT
comparisons/NNS
between/IN
groups/NNS
in/IN
these/DT
6/CD
cancers/NNS
,/,
G64/NN
up-regulation/NN
was/VBD
consistently/RB
observed/VBN
to/TO
be/VB
associated/VBN
with/IN
worse/NN
patient/NN
prognosis/NN
in/IN
the/DT
Cox/NN
regression/NN
analysis/NN
(/(
Fig/NN
./.
====================
1/CD
,/,
Supplementary/JJ
Fig/NN
./.
====================
3/CD
,/,
4/CD
,/,
5/CD
,/,
6/CD
,/,
7/CD
,/,
8/CD
)/)
./.
====================
The/DT
22/CD
cancers/NNS
were/VBD
subsequently/RB
divided/VBN
into/IN
two/CD
batches/NNS
:/:
i.e./FW
,/,
six/CD
survival-differentiating/VBG
cancers/NNS
and/CC
16/CD
survivalnon-/NN
differentiating/VBG
cancers/NNS
./.
====================
After/IN
the/DT
RNA-seq/NN
samples/NNS
from/IN
the/DT
22/CD
cancers/NNS
were/VBD
collected/VBN
as/IN
separate/JJ
batches/NNS
,/,
we/PRP
examined/VBD
the/DT
aspect/NN
of/IN
survival/NN
difference/NN
by/IN
G64/NN
expression/NN
in/IN
each/DT
batch/NN
./.
====================
Consequently/RB
,/,
the/DT
survival-differentiating/VBG
batch/IN
,/,
mixing/JJ
up/IN
six/CD
different/JJ
cancer/NN
samples/NNS
(/(
531/CD
+/CC
514/CD
+/CC
351/CD
+/CC
289/CD
+/CC
184/CD
+/JJ
257/CD
=/JJ
2,126/CD
samples/NNS
)/)
,/,
clearly/RB
maintained/VBD
the/DT
survival/NN
differentiation/NN
among/IN
the/DT
lowest/JJ
15/CD
%/NN
,/,
the/DT
highest/JJS
15/CD
%/NN
,/,
and/CC
the/DT
intermediate/JJ
groups/NNS
(/(
Fig/NN
./.
====================
2/CD
)/)
,/,
whereas/IN
the/DT
survival-non-differentiating/VBG
batch/NN
,/,
mixing/JJ
up/IN
16/CD
different/JJ
cancer/NN
samples/NNS
(/(
178/CD
+/JJ
373/CD
+/JJ
302/CD
+/JJ
…/NN
./.
====================
+/CC
179/CD
+/JJ
150/CD
=/JJ
5943/CD
samples/NNS
)/)
,/,
showed/VBD
no/DT
survival/NN
difference/NN
among/IN
the/DT
three/CD
different/JJ
groups/NNS
determined/VBN
by/IN
G64/NN
expression/NN
levels/NNS
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Taken/VBN
together/RB
,/,
the/DT
G64/NN
genes/NNS
can/MD
differentiate/VB
cancer/NN
samples/NNS
by/IN
their/PRP$
survival/NN
rate/NN
differences/NNS
in/IN
cancers/NNS
other/JJ
than/IN
LADC/NN
./.
====================
Basically/RB
,/,
it/PRP
was/VBD
an/DT
interesting/JJ
finding/NN
that/DT
genes/NNS
,/,
named/VBD
the/DT
G64/NN
module/NN
in/IN
our/PRP$
previous/JJ
study/NN
(/(
i.e./FW
,/,
a/DT
highly/RB
coregulated/VBN
gene/NN
group/NN
)/)
,/,
can/MD
classify/VB
not/RB
only/RB
single/JJ
cells/NNS
derived/VBN
from/IN
a/DT
single/JJ
tumor/NN
but/CC
also/RB
tumors/NNS
that/IN
have/VBP
originated/VBN
from/IN
several/JJ
different/JJ
cancers/NNS
./.
====================
Various/JJ
biomarkers/NNS
have/VBP
been/VBN
identified/VBN
and/CC
developed/VBD
for/IN
molecular/JJ
diagnostics/NNS
in/IN
cancers/NNS
./.
====================
In/IN
fact/NN
,/,
numerous/JJ
genes/NNS
included/VBD
in/IN
the/DT
list/NN
of/IN
the/DT
G64/NN
module/NN
have/VBP
already/RB
been/VBN
identified/VBN
as/IN
cancer/NN
diagnostic/JJ
or/CC
prognostic/JJ
markers/NNS
by/IN
several/JJ
independent/JJ
researchers/NNS
[/(
141516/CD
]/)
./.
====================
For/IN
instance/NN
,/,
CDCA5/NN
and/CC
NCAPH/NN
have/VBP
been/VBN
characterized/VBN
to/TO
be/VB
highly/RB
expressed/VBN
in/IN
lung/NN
cancers/NNS
[/(
1718/CD
]/)
./.
====================
Our/PRP$
previous/JJ
study/NN
showed/VBD
that/IN
cell/NN
cycle/NN
genes/NNS
were/VBD
a/DT
main/JJ
functional/JJ
GO/NN
category/NN
in/IN
the/DT
G64/NN
module/NN
./.
====================
Consistently/RB
,/,
dysregulation/NN
of/IN
the/DT
cell/NN
cycle/NN
has/VBZ
long/JJ
been/VBN
proven/VBN
to/TO
be/VB
a/DT
critical/JJ
process/NN
causing/VBG
cancers/NNS
[/(
19202122/CD
]/)
./.
====================
However/RB
,/,
to/TO
our/PRP$
knowledge/NN
,/,
it/PRP
was/VBD
the/DT
first/JJ
finding/NN
ever/RB
that/DT
G64/NN
genes/NNS
were/VBD
co-regulated/VBN
in/IN
various/JJ
cancers/NNS
,/,
and/CC
patient/NN
prognosis/NN
can/MD
be/VB
differentiated/VBN
by/IN
these/DT
genes/NNS
./.
====================
Here/RB
,/,
we/PRP
clearly/RB
showed/VBD
that/IN
the/DT
G64/NN
module/NN
can/MD
be/VB
a/DT
good/JJ
biomarker/NN
,/,
predicting/VBG
cancer/NN
prognosis/NN
at/IN
least/JJS
for/IN
six/CD
different/JJ
cancers—i.e./FW
,/,
seven/CD
different/JJ
cancers/NNS
if/IN
LADC/NN
is/VBZ
included/VBN
./.
====================
It/PRP
is/VBZ
unclear/JJ
what/WP
common/JJ
molecular/JJ
characteristics/NNS
the/DT
seven/CD
cancers/NNS
(/(
i.e./FW
,/,
6/CD
cancers/NNS
in/IN
the/DT
present/JJ
study/NN
and/CC
LADC/NN
)/)
share/VBP
together/RB
other/JJ
than/IN
co-regulated/JJ
G64/NN
expression/NN
./.
====================
The/DT
seven/CD
cancers/NNS
must/MD
be/VB
initiated/VBN
and/CC
progress/VBP
by/IN
different/JJ
genetic/JJ
or/CC
environmental/JJ
causes/VBZ
and/CC
pathways/NNS
,/,
and/CC
there/EX
is/VBZ
no/DT
proper/JJ
explanation/NN
for/IN
the/DT
common/JJ
subpopulation/NN
differentiation/NN
carried/VBN
through/IN
G64/NN
expression/NN
./.
====================
It/PRP
is/VBZ
also/RB
hard/VBP
to/TO
explain/VB
at/IN
this/DT
moment/NN
why/WRB
the/DT
64/CD
genes/NNS
are/VBP
co-regulated/VBN
on/IN
an/DT
inter-tumoral/JJ
level/NN
and/CC
intra-tumoral/JJ
level/NN
and/CC
why/WRB
up-regulating/VBG
patients/NNS
tend/VBP
to/TO
have/VB
a/DT
poor/JJ
prognosis/NN
./.
====================
One/CD
possibility/NN
we/PRP
can/MD
think/VB
of/IN
is/VBZ
that/DT
expression/NN
of/IN
these/DT
genes/NNS
may/MD
be/VB
associated/VBN
with/IN
drug/NN
metabolism/NN
,/,
contributing/VBG
to/TO
drug/NN
sensitivity/NN
or/CC
drug/NN
resistance/NN
./.
====================
It/PRP
will/MD
be/VB
interesting/JJ
to/TO
study/VB
further/RB
how/WRB
expression/NN
of/IN
G64/NN
is/VBZ
changed/VBN
during/IN
the/DT
recurrence/NN
of/IN
cancers/NNS
./.
====================
Taken/VBN
together/RB
,/,
G64/NN
genes/NNS
would/MD
be/VB
a/DT
good/JJ
candidate/NN
of/IN
developing/VBG
prognostic/JJ
markers/NNS
for/IN
multiple/JJ
cancers/NNS
./.
====================
Heat/NN
map/VBP
,/,
principal/JJ
component/NN
analysis/NN
(/(
PCA/NN
)/)
,/,
and/CC
Kaplan/JJ
Meier/NNP
(/(
KM/NN
)/)
plot/NN
analysis/NN
of/IN
G64/NN
in/IN
kidney/NN
renal/JJ
clear/JJ
cell/NN
carcinoma/NN
(/(
KIRC/NN
)/)
./.
====================
(/(
A/DT
)/)
Heat/NN
map/VBP
was/VBD
plotted/VBN
using/VBG
the/DT
160/CD
samples/NNS
corresponding/VBG
to/TO
the/DT
highest/JJS
15/CD
%/NN
and/CC
lowest/JJS
15/CD
%/NN
of/IN
G64/NN
expression/NN
among/IN
the/DT
total/JJ
of/IN
531/CD
KIRC/NN
samples/NNS
./.
====================
(/(
B/NN
)/)
A/NN
PCA/NN
plot/NN
of/IN
G64/NN
expression/NN
was/VBD
performed/VBN
using/VBG
the/DT
531/CD
KIRC/NN
samples/NNS
./.
====================
Low/JJ
,/,
the/DT
lowest/JJS
15/CD
%/NN
group/NN
;/:
INT/NN
,/,
intermediate/JJ
group/NN
;/:
High/JJ
,/,
the/DT
highest/JJS
15/CD
%/NN
group/NN
./.
====================
(/(
C/NN
)/)
KM/NN
analysis/NN
of/IN
the/DT
531/CD
KIRC/NN
samples/NNS
based/VBN
on/IN
the/DT
average/NN
G64/NN
expression/NN
./.
====================
Cox/NN
regression/NN
analysis/NN
was/VBD
used/VBN
to/TO
investigate/VB
whether/IN
the/DT
survival/NN
duration/NN
of/IN
the/DT
two/CD
different/JJ
groups/NNS
was/VBD
significantly/RB
different/JJ
(/(
p/NN
</JJR
0.001/CD
)/)
,/,
as/IN
shown/VBN
in/IN
Table/JJ
1/CD
./.
====================
KM/NN
analysis/NN
of/IN
combined/JJ
samples/NNS
of/IN
cancers/NNS
on/IN
expression/NN
of/IN
G64/NN
./.
====================
(/(
A/DT
)/)
KM/NN
plot/NN
of/IN
the/DT
combined/JJ
six/CD
samples/NNS
of/IN
the/DT
survival-differentiating/VBG
cancers/NNS
by/IN
G64/NN
,/,
including/VBG
kidney/NN
renal/JJ
clear/JJ
cell/NN
carcinoma/NN
,/,
brain/NN
lower-grade/JJ
glioma/NN
,/,
liver/NN
hepatocellular/JJ
carcinoma/NN
,/,
kidney/NN
renal/JJ
papilloma/NN
cell/NN
carcinoma/NN
,/,
esophageal/JJ
carcinoma/NN
,/,
and/CC
sarcoma/NN
(/(
see/VB
Table/JJ
1/CD
,/,
upper/IN
six/CD
cancers/NNS
)/)
./.
====================
(/(
B/NN
)/)
KM/NN
plot/NN
of/IN
the/DT
16/CD
remaining/VBG
samples/NNS
of/IN
the/DT
survivalnon-/NN
differentiating/VBG
cancers/NNS
(/(
see/VB
Table/JJ
1/CD
,/,
lower/JJR
16/CD
cancers/NNS
)/)
./.
====================
Low/JJ
,/,
the/DT
lowest/JJS
15/CD
%/NN
group/NN
;/:
INT/NNP
,/,
intermediate/JJ
group/NN
;/:
High/JJ
,/,
the/DT
highest/JJS
15/CD
%/NN
group/NN
;/:
HR/NN
,/,
hazard/RB
ratio/NN
;/:
95/CD
%/NN
CI/NN
,/,
95/CD
%/NN
confidence/NN
interval/JJ
./.
====================
List/NN
of/IN
the/DT
22/CD
cancers/NNS
====================
